Nurix Therapeutics (NASDAQ:NRIX) Issues Quarterly Earnings Results

Nurix Therapeutics (NASDAQ:NRIX) issued its earnings results on Tuesday. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08), Zacks reports. Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%.

Nurix Therapeutics Stock Down 1.3 %

Shares of NRIX stock opened at $19.56 on Wednesday. The stock has a 50-day simple moving average of $20.20 and a 200 day simple moving average of $22.42. Nurix Therapeutics has a fifty-two week low of $7.65 and a fifty-two week high of $29.56. The stock has a market capitalization of $1.39 billion, a P/E ratio of -6.72 and a beta of 2.14.

Insider Buying and Selling at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 3,546 shares of the stock in a transaction on Friday, November 1st. The stock was sold at an average price of $24.28, for a total transaction of $86,096.88. Following the completion of the sale, the chief financial officer now owns 33,724 shares in the company, valued at approximately $818,818.72. This represents a 9.51 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on NRIX shares. BTIG Research began coverage on shares of Nurix Therapeutics in a research note on Tuesday, December 10th. They set a “buy” rating and a $35.00 price objective on the stock. UBS Group started coverage on Nurix Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $35.00 price target on the stock. HC Wainwright boosted their price objective on Nurix Therapeutics from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday. Royal Bank of Canada dropped their target price on Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating on the stock in a research report on Monday, October 14th. Finally, Stephens reissued an “overweight” rating and set a $31.00 price target on shares of Nurix Therapeutics in a report on Tuesday, January 21st. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, Nurix Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $30.88.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.